A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.

  title={A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.},
  author={Uriel Heresco-Levy and Genia Gelfin and Boaz Bloch and Raz Levin and Shani Edelman and D. C. Javitt and Ilana Kremer},
  journal={The international journal of neuropsychopharmacology},
  volume={16 3},
Antagonism of N-methyl-D-aspartate glutamatergic receptors (NMDAR) may represent an effective antidepressant mechanism. D-cycloserine (DCS) is a partial agonist at the NMDAR-associated glycine modulatory site that at high doses acts as a functional NMDAR antagonist. Twenty-six treatment-resistant major depressive disorder patients participated in a double blind, placebo-controlled, 6-wk parallel group trial with a gradually titrated high dose (1000 mg/d) of DCS added to their antidepressant… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 44 extracted citations


Publications referenced by this paper.
Showing 1-10 of 25 references

BDI-II Manual

  • AT Beck, RA Steer, GK Brown
  • San Antonio, USA: The Psychological Corporation…
  • 1996
Highly Influential
2 Excerpts

The promising role of the glutamate system in mood disorders

  • CA Zarate, HK Manji
  • : Heresco-Levy U, Javitt DC (Eds.), Glutamate in…
  • 2008
3 Excerpts

Similar Papers

Loading similar papers…